parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.02 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including microglia; strongest in thyrotrophs	0.75
chemistry Open Targets	hard to drug	0.00
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	4 Parkinson's papers of 41	0.79
pathways Reactome	1 pathway; mostly other	0.30

No case: the score is under the bar. Receipt 8430

HIVEP3 in microglia, braak+0.32 (p 0.407) → +0.38 (p 0.316)receipt 8439
HIVEP3 in dopamine neurons, braak+0.37 (p 0.329) → -0.67 (p 0.049)receipt 8440

receipt 8440: HIVEP3 in dopamine neurons, braak

power: full sample -0.20 (p 0.429, n 18), 95% CI -0.61 to +0.30. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.20 (p 0.429, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.48 (p 0.042, n 18). not the mix.
skeptic: leave-one-out range -0.32 to -0.10, sign flips 0; without severely affected donors -0.20 (p 0.429, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for HIVEP3 in dopamine neurons.

case closed: nothing better to follow up.

receipt 8439: HIVEP3 in microglia, braak

power: full sample +0.28 (p 0.269, n 18), 95% CI -0.22 to +0.66. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.27 (p 0.277, n 18). does not hold up.
composition: microglia share of nuclei vs axis -0.11 (p 0.652); controlling for it: +0.17 (p 0.498, n 18). could be the mix.
skeptic: leave-one-out range +0.17 to +0.46, sign flips 0; without severely affected donors +0.28 (p 0.269, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for HIVEP3 in microglia.

case closed: nothing better to follow up.

loading the receipts